Vendor UpdateGastrointestinal Cancer

Cryoablation Successfully Treats Kidney Tumors

By News Release

 

IceCure Medical Ltd, developer of the ProSense System cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced the latest release of a study in a series of independent studies of ProSense published in peer-reviewed journals demonstrating safety and efficacy. The Study, titled "Single-Probe Percutaneous Cryoablation with Liquid Nitrogen for the Treatment of T1a Renal Tumors", published in Cancers, demonstrated the safety and efficacy of ProSense in treating malignant small renal masses. The Study was authored by eight physicians in France, including interventional radiologists and urologists from Curie Institute, Paris, Nîmes University Hospital (University of Montpellier), Nîmes, and Carémeau University Hospital, Nîmes.

ProSense is approved for the treatment of benign and malignant kidney tumors in the U.S., Europe, and numerous other countries.

The objective of this retrospective Study was to address the challenges of managing small renal masses, including recurrence rates, by exploring the safety and efficiency of single-probe percutaneous cryoablation as a potential solution. The causes of partial tumor response and persistent tumor residue after a T1a renal cryoablation procedure were assessed. A total of 25 patients underwent cryoablation for 26 T1a renal tumors with a median tumor size of 25.3 mm (20 to 30.7 mm) and a median RENAL nephrometry score, indicating tumor complexity, of 7 (5 to 9).

The Study’s main findings include:

  • Disease-free survival rate was 92% (23 out of 25) at a median follow-up of 26 and a half months
  • Recurrent lesions were treated again using cryoablation, achieving a secondary local control rate of 100%
  • No patients died
  • No major complications arose
  • 4% of patients (N= 24) were discharged the day after surgery

One of the Study's authors, Professor Julien Frandon, Director of the Interventional Radiology Department at Nîmes University Hospital commented, "In our recent publication, we evaluated the safety and efficacy of IceCure's cryoablation technology for the treatment of renal T1a tumors. This innovative approach has demonstrated remarkable safety profiles, even for challenging and unfavorably located small renal masses. One of the study's crucial findings is the technology's ability to preserve renal function post-treatment, which is paramount for patients' quality of life. This technology stands out as a forward-thinking solution in oncological treatment, providing a combination of patient safety, procedural efficiency, and cost-effectiveness."

"We appreciate the diligent work of Professor Frandon and his colleagues in conducting this Study and we congratulate them on its publication in Cancers, a prestigious European medical journal," stated IceCure's Chief Executive Officer Eyal Shamir. "The authors' findings are similar to the interim results from our own ICESECRET study in small renal masses which demonstrated an 89.5% recurrence-free rate. We expect ICESECRET's five-year patient follow-up to be completed in 2026, with topline results available shortly afterwards."